Mission Bio Information

Mission Bio is the single-cell multiomics company behind the Tapestri Platform. Tapestri measures DNA, RNA, protein, and epigenetics in the same cell, so scientists can link genotype to phenotype and see what drives disease progression, resistance, and response to therapy. Single-cell measurable residual disease (MRD) is a core application. Single-cell MRD on Tapestri improves clinical sensitivity, so clinicians can monitor patients and detect relapse more effectively than with current standard-of-care methods. Tapestri is built on targeted single-cell DNA sequencing. It detects single nucleotide variants, insertions and deletions, gene edits, and copy number variations alongside surface protein expression, targeted gene expression, and epigenetics. Researchers use it in hematologic malignancies, solid tumors, and cell and gene therapy, including CAR-T safety assessment, drug molecule characterization, and genome integrity analysis. The Assay Services team designs purpose-built custom panels with pharmaceutical and biotech partners to evaluate drug molecules in discovery and clinical development programs. Mission Bio spun out of Adam Abate’s lab at the University of California, San Francisco in 2014. Tapestri combines his droplet microfluidics work with new biochemistry and bioinformatics.